Exploring Protein Misfolding and Aggregate Pathology in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Interventions
Open Access
- 22 September 2025
- journal article
- review article
- Published by MDPI AG in Applied Sciences
- Vol. 15 (18) , 10285
Abstract
Neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease are characterized by progressive neuronal loss, driven mainly by the misfolding, aggregation, and accumulation of each disease’s specific proteins. These pathogenic aggregates, including tau, α-synuclein, TDP-43, and huntingtin, disrupt cellular proteostasis and initiate cascades of neuroinflammation, oxidative stress, mitochondrial dysfunction, and synaptic failure. While protein aggregation has been a long-recognized hallmark of these disorders, growing evidence points towards a more complex interplay of initial molecular pathways with defects in RNA processing, stress granule pathology, and cell-type-specific vulnerability. Notably, such events may manifest differentially with respect to sex and are further modulated by age-related loss of the protein quality control processes like the ubiquitin–proteasome pathway, autophagy–lysosome pathway, and molecular chaperones. This review synthesizes current insights into the structural and functional dynamics of protein aggregation and its significance for neuronal well-being. It highlights the role of post-translational modifications, prion-like transmission, and aggregation kinetics in the regulation of toxicity. The review further discusses promising therapeutic strategies centered on restoring proteostasis, including small molecules that inhibit aggregation, protein clearance pathway enhancers, immunotherapy, antioxidant therapy, and diagnostic prospects such as the identification of reliable molecular signatures in bodily fluids that can reflect pathological changes even before clinical symptoms emerge. Advancements in single-cell transcriptomics and multi-omics platforms, which are changing our understanding of disease onset and progression and opening avenues for precision medicine and personalized treatments, were also discussed. Ultimately, deciphering the molecular logic that distinguishes physiological from pathological protein assemblies and understanding how cellular systems fail to adapt under stress will be key to the development of effective, disease-modifying therapies for these debilitating disorders.Keywords
This publication has 250 references indexed in Scilit:
- Validating the Accuracy of Parkinson's Disease Clinical Diagnosis: A UK Brain Bank Case–Control StudyAnnals of Neurology, 2025
- Amyloid Positron Emission Tomography and Subsequent Health Care Use Among Medicare Beneficiaries With Mild Cognitive Impairment or DementiaJAMA Neurology, 2023
- Amyloid fibrils act as a reservoir of soluble oligomers, the main culprits in protein deposition diseasesBioEssays, 2022
- Splicing and neurodegeneration: Insights and mechanismsWIREs RNA, 2019
- Development of a Biochemical Diagnosis of Parkinson Disease by Detection of α-Synuclein Misfolded Aggregates in Cerebrospinal FluidJAMA Neurology, 2017
- Proteomics in neurodegenerative diseases: Methods for obtaining a closer look at the neuronal proteomeProteomics – Clinical Applications, 2014
- RNA‐binding proteins in neurodegenerative disease: TDP‐43 and beyondWIREs RNA, 2011
- Bacterial Inclusion Bodies of Alzheimer's Disease β‐Amyloid Peptides Can Be Employed To Study Native‐Like Aggregation Intermediate StatesChemBioChem, 2011
- Calcium ions in neuronal degenerationIUBMB Life, 2008
- Heterogeneous Nucleation-Controlled Particulate Formation of Recombinant Human Platelet-Activating Factor Acetylhydrolase in Pharmaceutical FormulationJournal of Pharmaceutical Sciences, 2005